Skip to main content

Table 3 p-values and median percent changes [p value/median change (%)] of DVH OAR and target volume parameters when comparing the re-optimized versus the predicted dose distributions

From: Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate

 

Liver

Lung

Lymph nodes

Pancreas

Prostate

OAR

0.000/6.9

0.004/5.9

0.001/−4.5

0.000/−87.0

0.135/0.8

PTV Dmean

0.000/3.8

0.006/1.0

0.000/3.0

0.041/0.8

0.000/0.9

PTV D2%

0.712/0.1

0.131/−0.7

0.757/0.0

0.002/−0.9

0.093/−0.2

PTV D50%

0.001/2.6

0.065/0.0

0.003/0.9

0.196/−0.5

0.021/0.3

PTV D95%

0.000/17.3

0.000/6.0

0.000/9.4

0.000/5.7

0.000/2.8

PTV D98%

0.000/25.5

0.000/7.8

0.000/15.6

0.000/11.0

0.000/5.8

GTV or CTV Dmean*

0.004/1.0

0.012/0.9

0.000/1.4

0.454/−1.3

0.007/0.4

GTV or CTV D2%

0.872/0.0

0.042/−0.4

0.949/−0.2

0.176/−0.8

0.176/−0.1

GTV or CTV D50%

0.040/0.6

0.127/0.6

0.020/1.0

0.164/−1.4

0.185/0.2

GTV or CTV D95%

0.001/4.6

0.000/3.1

0.000/4.9

0.946/−0.3

0.000/0.7

GTV or CTV D98%

0.000/6.3

0.000/3.9

0.000/6.8

0.589/0.5

0.000/1.3

  1. Significant differences are highlighted bold
  2. *GTV for all subgroups except prostate and CTV for prostate